References
- Busse R, Orvain J, Velasco M et al. Best practice in undertaking and reporting health technology assessments. Int. J. Technol. Assess. Health Care 18, 361–442 (2002).
- Hailey D. Toward transparency in health technology assessment: a checklist for HTA reports. Int. J. Technol. Assess. Health Care 19(1), 1–7 (2003).
- Creditor MC, Beetle JK. The information base for diffusion of technology: computed tomography scanning. N. Engl. J. Med. 297(1), 49–52 (1977).
- Lehoux P, Blume S. Technology assessment and the sociopolitics of health technologies. J. Health Polit. Policy Law 25(6), 1083–1120 (2000).
- Jonsson E. Development of health technology assessment in Europe. A personal perspective. Int. J. Technol. Assess. Health Care 18(2), 171–183 (2002).
- Werkö L, Banta D. Report from the EUR-ASSESS Project. Int. J. Technol. Assess. Health Care 11(4), 797–799 (1995).
- Jonsson E, Banta HD, Henshall C, Sampietro-Colom L. Executive summary of the ECHTA/ECAHI project. European Collaboration for Health Technology Assessment/Assessment of Health Interventions. Int. J. Technol. Assess. Health Care 18(2), 213–217 (2002).
- Banta D, Oortwijn W. Introduction: health technology assessment and the European Union. Int. J. Technol. Assess. Health Care 16(2), 299–302 (2000).
- Velasco-Garrido M, Busse R. Health Technology Assessment: An Introduction to Objectives, Role of Evidence, and Structure in Europe. European Observatory on Health Systems and Policies, World Health Organization, Brussels, Belgium (2005).
- Wanke M, Juzwishin D, Thornley R, Chan L. An Exploratory Review of Evaluations of Health Technology Assessment Agencies. Alberta Heritage, Alberta, Canada (2006).
- Drummond MF, Schwartz JS, Jönsson B et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int. J. Technol. Assess. Health Care 24(3), 244–258; discussion 362 (2008).
- Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost–effectiveness analysis in health-care resource allocation decision-making: how are cost–effectiveness thresholds expected to emerge? Value Health 7(5), 518–528 (2004).
- George B, Harris A, Mitchell A. Cost–effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19(11), 1103–1109 (2001).
- Laufer F. Thresholds in cost–effectiveness analysis – more of the story. Value Health 8(1), 86–87 (2005).
- Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost–effectiveness. Risk Anal. 15(3), 369–390 (1995).
- Johannesson M, Meltzer D. Some reflections on cost–effectiveness analysis. Health Econ. 7(1), 1–7 (1998).
- Bridges JF, Onukwugha E, Mullins CD. Healthcare rationing by proxy: cost–effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics 28(3), 175–184 (2010).
- Culyer T, Lomas J. Deliberative processes and evidence-informed decision making in healthcare: do they work and how might we know? Evid. Policy 2, 357–371 (2006).
- Liberati A, Sheldon TA, Banta HD. EUR-ASSESS Project subgroup report on methodology: methodological guidance for the conduct of health technology assessment. Int. J. Technol. Assess. Health Care 13(2), 186–219 (1997).
- Kolasa K, Wasiak R. Health technology assessment in Poland and Scotland: comparisons of processes and decisions. Int. J. Technol. Assess. Health Care 28(1), 70–76 (2012).
- Szende Á, Mogyorósy Z, Muszbek N, Nagy J, Pallos G, Dózsa CS. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards. Eur. J. Health Econ. 3(3), 196–202 (2002).
- Gallo P. Integrating ethical enquiry and health technology assessment: limits and opportunities for efficiency and equity. Poiesis Prax. 2, 103–117 (2004).
- Boncz I, Dozsa C, Kalo Z et al. Development of health economics in Hungary between 1990–2006. Eur. J. Health Econ. 7 (Suppl. 1) (2006).
- Ministerial Decree on the Inclusion of New Pharmaceuticals and Medical Nutrition Products to the Reimbursement List. Hungarian Ministry of Health, Social and Family Affairs 32/2004 (IV. 26.) (2004).
- Gulácsi L, Boncz I, Drummond M. Issues for countries considering introducing the ‘fourth hurdle’: the case of Hungary. Int. J. Technol. Assess. Health Care 20(3), 337–341 (2004).
- Kaló Z, Docteur E, Moïse P. Pharmaceutical Pricing and Reimbursement Policies in Slovakia (OECD Health Working Paper, No. 31). OECD/OCDE, Paris, France (2008).
- Kolasa K, Schubert S, Manca A, Hermanowski T. A review of health technology assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy 102(2–3), 145–151 (2011).
Websites
- European Commission Transparency Directive 89/105/EEC. http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/pricing-reimbursement/transparency/index_en.htm (Accessed 1 June 2011)
- International Network for Agencies in Health Technology Assessment. www.inahta.org (Accessed 21 January 2012)
- ISPOR 13th Annual European Congress. Health policy development using outcomes research issues panel. www.ispor.org/congresses/Prague1110/issuepanels.asp (Accessed 11 February 2012)
- Burzyńska AR. The republic: dangerous liaisons. Rzeczpospolita. www.rzeczpospolita.pl (Accessed 12 January 2012)
- EFPIA. The use of health technology assessment to evaluate medicines: key principles. www.eunethta.net/upload/Stakeholder_Forum/SWLA/Stakeholder%20Position%20Papers/EFPIAs_HTA_Principles.pdf (Accessed 14 October 2010)
- Ministry of Health. The Polish reimbursement healthcare act no. 122, 12 May 2011. www.mz.gov.pl (Accessed 12 January 2012)
- European Commission Transparency Directive Review of the Directive. http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/pricing-reimbursement/transparency/index_en.htm#h2-4 (Accessed 11 February 2012)